Suvretta Capital Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-700,904
| Closed | -$92.5M | – | 114 |
|
|
2025
Q1 | $92.5M | Sell |
700,904
-738,122
| -51% | -$92M | 3.74% | 9 |
|
|
2024
Q4 | $120M | Hold |
1,439,026
| – | – | 4.45% | 4 |
|
|
2024
Q3 | $105M | Sell |
1,439,026
-126,970
| -8% | -$9.54M | 3.78% | 5 |
|
|
2024
Q2 | $107M | Buy |
1,565,996
+606,798
| +63% | +$42.1M | 4.38% | 5 |
|
|
2024
Q1 | $66.4M | Sell |
959,198
-206,750
| -18% | -$14.2M | 2.8% | 12 |
|
|
2023
Q4 | $83.5M | Sell |
1,165,948
-203,901
| -15% | -$11.7M | 3.82% | 7 |
|
|
2023
Q3 | $71.4M | Buy |
1,369,849
+170,878
| +14% | +$9.96M | 3.86% | 9 |
|
|
2023
Q2 | $75.9M | Hold |
1,198,971
| – | – | 4.06% | 5 |
|
|
2023
Q1 | $64.9M | Buy |
1,198,971
+162,023
| +16% | +$7.83M | 3.13% | 11 |
|
|
2022
Q4 | $54.9M | Buy |
1,036,948
+184,990
| +22% | +$9.27M | 2.3% | 15 |
|
|
2022
Q3 | $39.6M | Sell |
851,958
-486,742
| -36% | -$25.4M | 1.67% | 27 |
|
|
2022
Q2 | $76.4M | Sell |
1,338,700
-193,223
| -13% | -$11M | 2.91% | 8 |
|
|
2022
Q1 | $93.7M | Buy |
1,531,923
+279,977
| +22% | +$14.5M | 2.86% | 9 |
|
|
2021
Q4 | $65.5M | Hold |
1,251,946
| – | – | 1.27% | 28 |
|
|
2021
Q3 | $46.7M | Buy |
1,251,946
+213,176
| +21% | +$7.41M | 0.79% | 37 |
|
|
2021
Q2 | $42.4M | Hold |
1,038,770
| – | – | 0.64% | 41 |
|
|
2021
Q1 | $35.2M | Buy |
1,038,770
+132,800
| +15% | +$4.61M | 0.52% | 46 |
|
|
2020
Q4 | $28.8M | Buy |
905,970
+413,700
| +84% | +$10.9M | 0.41% | 48 |
|
|
2020
Q3 | $12.6M | Buy |
+492,270
| New | +$11.2M | 0.23% | 48 |
|
Other funds holding ITCI
KIM
HNB